Loading…
Loading…
Both companies pay relatively high-yield dividends. One marries this with growing fundamentals, while the other is basically in reset mode.
AbbVie posted strong Phase 2a results for a potential successor to Skyrizi in Crohn's disease. The company also has a promising eczema candidate that could cement its position in immunology.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidra
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physicians Lutikizumab was generally well tolerated, with no new safety concerns identified1 INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).
Three popular dividend stocks are paying out well above their free cash flow, and the gap between what each one earns and what it sends to shareholders reveals very different risks hiding behind familiar, trusted names.
